Download
1 / 40
400 likes | 539 Views
SRCL Presentation for RCMP. By: Joe Vaccaro , Paul Ripsky , Bilal Rathore , Christina Guang Lu 04/09/2009. Current Position and Recommendation. Purchased 200 shares in March 2001 2:1 split twice Sold 200 shares in March 2006 and again in November 2008 Currently own 200 shares @ $51.27
E N D
SRCL Presentation for RCMP By: Joe Vaccaro, Paul Ripsky, BilalRathore, Christina Guang Lu 04/09/2009
Current Position and Recommendation • Purchased 200 shares in March 2001 • 2:1 split twice • Sold 200 shares in March 2006 and again in November 2008 • Currently own 200 shares @ $51.27 • Unrealized gain of $8,307.12 • We recommend to sell 100 shares of SRCL at the market price of $51.80 (4/9)
Company History Founded in 1989 after the passage of the Medical Waste Tracking Act Launched IPO in 1996 Started International operations in 1998 Emerged as North America's largest provider of medical waste services in 2000. Acquired Bio System Sharps in 2003
Company Overview Offers collection, transportation, treatment, disposal, and recycling of medical waste Full service for nearly 400,000 customers Foreign customers nearly 23% of revenues No single customer accounts for greater than 2% of revenues.
Stericycle has two main clients: • Large Quantity Generators (LQGs) • Hospitals, distributors, and pharmaceutical companies • Bio Systems aids LQGs in the disposal of needles and syringes • Small Quantity Generators (SQGs) • Doctors' offices and retail pharmacies • SQGs use SteriSafe to dispose of RMW (radioactive mixed wastes).
Products and Services Medical Waste Disposal Specialize in the collection, treatment and disposal of medical and bio-hazardous waste Ensure maximum infection control and documentation necessary for compliance Route Managers carry out responsibilities discreetly, without interrupting operation Provide staff training and education to help protect employees and reduce risk
Products and Services Sharp Disposal Hospitals Private Practices: Medical and dental offices Home Sharp Users: Patients with conditions such as arthritis, diabetes and cancer Community Collection Programs *The CDC estimates that over 800,000 needle sticks occur each year among healthcare workers
Business Model 2. Transfer Stations 4. 1. 3. Recycling or Permanent Disposal Collection of regulated waste Processing Facility -Supply reusable leak-and puncture-resistant plastic container -Collect containers of regulated waste at intervals specified by contract -Allows temporary hold of small loads of waste -Consolidated into full truckloads then transported to processing facility -Scanned to check for unacceptable hazardous materials -Resulting waste sent to resource recovery, recycling or disposal landfill
National Coverage 45 Treatment stations 100 Transfer stations 1200 Route Managers Uniquely prepared to respond promptly to natural or internal disaster
Macro-economic Outlook Medical waste Industry historically less volatile during times of recession • There is very consistent demand for the service and thus a fairly consistent revenue stream based on the demand. • There will always be a need to collect trash and dispose of it. • Stericycle has approximately 400,000 customers, which are well diversified internationally • The medical waste industry is tightly regulated • Stricter regulations imposed on disposing medical waste leads to greater demand for Stericycle's services. • Long-term as the baby boomers age, more treatment equals more waste.
Macro-economic Outlook Price of Oil (hedging against risk) • Most companies that are highly dependent on transportation have seen a large impact to the downside in their stock price due to the volatility of oil • Stericycle has 1200 Route Managers • Many Waste Services companies have implemented ways to hedge against high oil. • Stericycle has a fuel surcharge program that is designed to minimize the damage to margins from high and volatile oil.
Management Team • Over 150 years of management experience in the health care, consumer, and waste management industries by the top 6 executives • Mark C. Miller—Chairman, President, and CEO • Richard T. Kogler—Exec. VP and COO • Frank J.M. ten Brink—Exec. VP and CFO • Richard L. Foss—Exec. VP, International • Michael J. Collins—President, Return Management Services • Richard J. Marasco—Exec. VP, M&A
Industry Overview • Regulated medical waste is generally any medical waste that can cause an infectious disease • Items such as needles, syringes, gloves and other medical supplies; cultures and stocks of infectious agents; and blood and blood products • Regulated pharmaceutical waste consists of expired or recalled pharmaceuticals • Global regulated waste industry size in 2008: $10.5 billion • Stericycle’s global market share: 10.3% (increased from 9.3% in 2007) • Highly regulated industry • U.S. Environmental Protection Agency, U.S. Department of Transportation, U.S. Postal Service, Occupational Safety and Health Administration, Drug Enforcement Administration • Very fragmented
Industry Growth Factors • Aging population • Pressure to reduce healthcare costs • Environmental and safety regulations • Shift from institutional higher-cost acute-care settings to less expensive, smaller, offsite treatment alternatives • Results in increase in the number of regulated waste generators that cannot treat their own regulated waste
SWOT Analysis • Strengths • Market leader • Broad range of services • Established network of treatment facilities and transportation • Revenue stability and noncyclical business • Experienced senior management team • Ability to integrate acquisitions (157 since 1993) • Proprietary technology (i.e. ETD)
SWOT Analysis • Strengths • Diverse customer base • Top 10 account for 7% of revenues • No one customer accounts for more than 2% of revenues • 418,000 customers • 11,000 large-quantity generators, such as hospitals, blood banks and pharmaceutical manufacturers • 407,000 small-quantity generators, such as outpatient clinics, medical and dental offices, long-term and sub-acute care facilities and retail pharmacies
SWOT Analysis • Weaknesses • Subject to extensive governmental regulation, which is usually difficult, expensive, and time-consuming to comply with • Exposure to environmental liabilities which may not be covered by insurance • Patents for ETD start to expire in May 2009 • Inability to complete acquisitions may slow down revenue and profit growth
SWOT Analysis • Opportunities • Very fragmented industry provides acquisition opportunities • Growing global market • High demand by small-quantity generators
DCF Analysis Assumptions 2009 Management Forecast in 2008 Q4 Earning Call • Total revenue: in the range of $1.16 b to $1.18b • Net Income: in the range of $165m to $ 179 m • Free Cash Flow: in the range of $165m to $185m
DCF Model • Equity Price: $ 44.90 WACC= 9.86%
Sensitivity Analysis • Equity Price: $ 41.46 ~ 53.61
Competitors (2) 3. Steris Corp. (NYSE:STE) STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and critical care support products and services to healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company, formerly known as Innovative Medical Technologies, was founded in 1985 and is headquartered in Mentor, Ohio. 4. Waste Management, Inc. (NYSE:WMI) Waste Management, Inc. provides integrated waste management services in North America. The company offers collection, transfer, recycling, disposal, and waste-to-energy services. The company also provides additional waste management services, such as in-plant services, methane gas recovery, and third party sub-contracted and administrative services. It serves commercial, industrial, municipal, and residential customers, as well as other waste management companies, electric utilities, and governmental entities. The company was formerly known as USA Waste Services, Inc. and changed its name to Waste Management, Inc. in 1998. Waste Management, Inc. was founded in 1894 and is based in Houston, Texas.
RMCP Portfolio SRCL: 3.43% Before Sale After Sale SRCL: 1.71%
Recommendation We recommend to SELL 100 shares of our current position at the market price • A re-evaluation of the position should be considered if the stock falls below $45 (Based on DCF evaluation) • Questions? • Comments?
